1Degli EE, Berto P, Ruffo P, et al. The PANDORA project: result of the cost of illness analysi. J Hum Hypertents. 2001. 15:329-334.
2Degli EE, Sturani A, Degli EL, et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther ,2001,39:251-258.
3Johannesson M, Dahlof B, Lintholm LH, et al. The cost-effectiveness of treating hypertension in elderly people-an analysis of the Swedish TrialOld Patients with Hypertension (STOP Hypertension). J Intern Med ,1993,234 : 317-323.
4Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, Pharm D. Am J Manag Care , 1999, 5( Suppl 7):S449-454.
5Dunn EC, Small RE. Economic of antihypertensive therapy in the elderly. Drugs Anging ,2001, 18: 515-525.
6Pearce KA, Furberg CD, Psaty BM, et al. Cost-mininization and the number need to treat in uncomplicated hypertension. Am J Hypertens,1998, 11:618-629.
7Ramsey SD, Neil N, Sullivan SD, et al. An economic evaluation of the JNC hypertension guidelines using data from randomized controlled trial. Am Board Fam Prac, 1999, 12: 105-114.
8Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Arch Intern Med, 2000, 160: 1277-1283.
